These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 26589440)

  • 1. Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer.
    Singh N; Singh PS; Aggarwal AN; Behera D
    Clin Lung Cancer; 2016 May; 17(3):205-213.e1. PubMed ID: 26589440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Comorbidity Scores on the Overall Survival of Patients With Advanced Non-small Cell Lung Cancer: A Real-World Experience From Eastern India.
    M SG; Mohapatra PR; Bhuniya S; Das Majumdar SK; Mishra P; Panigrahi MK; Bal SK; Datta A; Venkatachalam P; Chatterjee D
    Cureus; 2022 Oct; 14(10):e30589. PubMed ID: 36420233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
    Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
    J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Influence of Comorbidity and the Simplified Comorbidity Score on Overall Survival in Non-Small Cell Lung Cancer-A Prospective Cohort Study.
    Alexander M; Evans SM; Stirling RG; Wolfe R; Officer A; MacManus M; Solomon B; Burbury K; Ball D
    J Thorac Oncol; 2016 May; 11(5):748-757. PubMed ID: 26851495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of the simplified comorbidity score in the treatment of small cell lung carcinoma.
    Kuo YW; Jerng JS; Shih JY; Chen KY; Yu CJ; Yang PC
    J Thorac Oncol; 2011 Feb; 6(2):378-83. PubMed ID: 21173715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comorbidity in patients undergoing surgery for lung cancer. Do we have an adequate tool to assess it?
    Lembicz M; Gabryel P; Brajer-Luftmann B; Dyszkiewicz W; Batura-Gabryel H
    Adv Respir Med; 2017; 85(2):55-63. PubMed ID: 28440530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes in Elderly Patients Treated for Oral Cavity Squamous Cell Carcinoma.
    Chen JJ; Shah JL; Harris JP; Bui TT; Schaberg K; Kong CS; Kaplan MJ; Divi V; Schoppy D; Le QT; Hara WY
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):775-783. PubMed ID: 28602409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis.
    Hsu CL; Chen JH; Chen KY; Shih JY; Yang JC; Yu CJ; Yang PC
    J Geriatr Oncol; 2015 Jan; 6(1):38-45. PubMed ID: 25245172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simplified Graded Baseline Symptom Assessment in Patients With Lung Cancer Undergoing First-Line Chemotherapy: Correlations and Prognostic Role in a Resource-Constrained Setting.
    Singh PS; Aggarwal AN; Behera D; Kapoor R; Singh N
    J Glob Oncol; 2017 Feb; 3(1):54-63. PubMed ID: 28717742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.
    Halvorsen TO; Sundstrøm S; Fløtten Ø; Brustugun OT; Brunsvig P; Aasebø U; Bremnes RM; Kaasa S; Grønberg BH
    Acta Oncol; 2016 Nov; 55(11):1349-1354. PubMed ID: 27549509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer.
    Zhao L; Leung LH; Wang J; Li H; Che J; Liu L; Yao X; Cao B
    BMC Pulm Med; 2017 Aug; 17(1):112. PubMed ID: 28806935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
    Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results and impact of routine assessment of comorbidity in elderly patients with non-small-cell lung cancer aged > 80 years.
    Breen D; Barlési F; Zemerli M; Doddoli C; Torre JP; Thomas P; Astoul P
    Clin Lung Cancer; 2007 Mar; 8(5):331-4. PubMed ID: 17562233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy.
    Zeng X; Zhu S; Xu C; Wang Z; Su X; Zeng D; Long H; Zhu B
    Med Sci Monit; 2020 Sep; 26():e922576. PubMed ID: 32893263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index.
    Colinet B; Jacot W; Bertrand D; Lacombe S; Bozonnat MC; Daurès JP; Pujol JL;
    Br J Cancer; 2005 Nov; 93(10):1098-105. PubMed ID: 16234816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.
    Goyal J; Pond GR; Galsky MD; Hendricks R; Small A; Tsao CK; Sonpavde G
    Urol Oncol; 2014 Jan; 32(1):36.e27-34. PubMed ID: 23685020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Simplified Comorbidity Score (Colinet) as a prognostic indicator for patients with lung cancer: a cancer registry study.
    Ball D; Thursfield V; Irving L; Mitchell P; Richardson G; Torn-Broers Y; Wright G; Giles G
    Lung Cancer; 2013 Nov; 82(2):358-61. PubMed ID: 24051083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.